FOLH1 and pachyonychia congenita: According to Sterzing et al., radiotherapeutic management was changed in 51% of the patients after restaging with 68Ga-PSMA PET/CT-11 which suggests the possibility of selective and individualized therapeutic decision-making in patients with PC recurrence [30].